Stock Groups

Moderna raises full-year COVID vaccine sales forecast to $21 billion -Breaking

by Mike Robinson

[ad_1]

2/2
© Reuters. FILEPHOTO: In this illustration, a vial and sryinge can be seen facing a Moderna logo. This was taken on January 11, 2021. REUTERS/Dado Ruvic

2/2

(Reuters) – Moderna (NASDAQ:) Inc raised Thursday its full-year sales forecast for COVID-19 to $21 billion, from $19 billion.

According to February’s forecast, sales were $19 billion based on contracts that had been signed by the company. The option of $3 billion for additional purchases was also available.

Moderna predicted Thursday that additional purchases would be made in the range of $500 million.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]